High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience

Blana, Andreas; Walter, Bernhard; Rogenhofer, Sebastian; Wieland, Wolf F.

doi:10.1016/j.urology.2003.09.020

Cited by 316 publications

(192 citation statements)

References 20 publications

Supporting

Mentioning

177

Contrasting

Unclassified

Order By: Relevance

“…[12][13][14] Since May 2003, we have used transrectal HIFU treatment for localized prostate cancer using the Sonablate 500 machine. Our 7-year experience of 137 patients with clinical stage T1 or T2 prostate cancer shows that HIFU is easy to carry out, safe, noninvasive and repeatable; and has no major complications, although difficulty in voiding and grade 1 incontinence were observed in some patients after removal of the urethral catheter, and postoperative erectile dysfunction occurred in 37% of patients.…”

Section: Discussionmentioning

confidence: 99%

Transrectal high‐intensity focused ultrasound for treatment of localized prostate cancer

Inoue¹,

Goto²,

Hayashi³

et al. 2011

Int J of Urology

View full text Add to dashboard Cite

Objectives:To assess the long-term outcomes of transrectal high-intensity focused ultrasound (HIFU) for patients with localized prostate cancer. Methods: From May 2003 to present, 137 consecutive patients with T1-2 prostate cancer were treated using the Sonablate 500 and then followed for more than 12 months after their last HIFU treatment. A prostate biopsy was routinely carried out at 6 months and serum prostate-specific antigen (PSA) was measured every 3 months after HIFU. Oncological outcomes as well as treatment-related complications were assessed. Disease-free survival (DFS) was judged using the Phoenix definition (PSA nadir + 2 ng/mL), negative histological findings and no local or distant metastasis. Results:The median follow up after HIFU was 36 months (range 12-84 months). No patients received adjuvant therapy during this period. The PSA nadir occurred at 2 months after HIFU and the median level was 0.07 ng/mL (0.01-2.01 ng/mL). Of the 133 patients who underwent prostate biopsy or transurethral resection of the prostate at 6 months or later after HIFU, six were positive for cancer cells (4.5%). There were no major postoperative complications, but urge incontinence (16 cases) and dysuria (33 cases) occurred after removal of the urethral catheter. The 5-year DFS rate was 78% based on these criteria, and 91%, 81% and 62% in the low-, intermediate-and high-risk group, respectively. Conclusions: HIFU represents an effective, repeatable and minimally invasive treatment. It is particularly effective for low-and intermediate-risk patients, and it should be considered as an option for localized prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Transrectal high‐intensity focused ultrasound for treatment of localized prostate cancer

Inoue¹,

Goto²,

Hayashi³

et al. 2011

Int J of Urology

View full text Add to dashboard Cite

show abstract

“…Other groups are also generating results in different areas; an MRI-guided extracorporeal HIFU device (Exablate, Insightec Inc., Haifa, Israel) has been granted FDA approval for the treatment of uterine fibroids (Stewart et al, 2003), and trans-rectal HIFU devices are increasingly being used to treat localised prostate cancer in Europe (Blana et al, 2004).…”

Section: Kidneymentioning

confidence: 99%

The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population

et al. 2005

View full text Add to dashboard Cite

High-intensity focused ultrasound (HIFU) provides a potential noninvasive alternative to conventional therapies. We report our preliminary experience from clinical trials designed to evaluate the safety and feasibility of a novel, extracorporeal HIFU device for the treatment of liver and kidney tumours in a Western population. The extracorporeal, ultrasound-guided Model-JC Tumor Therapy System (HAIFUt Technology Company, China) has been used to treat 30 patients according to four trial protocols. Patients with hepatic or renal tumours underwent a single therapeutic HIFU session under general anaesthesia. Magnetic resonance imaging 12 days after treatment provided assessment of response. The patients were subdivided into those followed up with further imaging alone or those undergoing surgical resection of their tumours, which enabled both radiological and histological assessment. HIFU exposure resulted in discrete zones of ablation in 25 of 27 evaluable patients (93%). Ablation of liver tumours was achieved more consistently than for kidney tumours (100 vs 67%, assessed radiologically). The adverse event profile was favourable when compared to more invasive techniques. HIFU treatment of liver and kidney tumours in a Western population is both safe and feasible. These findings have significant implications for future noninvasive image-guided tumour ablation.

show abstract

“…1 With an actuarial 5-year disease-free survival rate at 66%, most authors still report 6-17% residual cancerous tissue in the patients treated. [2][3][4] The persistence of tumor cells after treatment is most often explained by the presence of a locally advanced understaged prostate cancer with extracapsular extensions, and given that the HIFU treatment is localized in the prostate these extraprostatic cells are therefore not destroyed. 5 From these diagnostic findings the importance was raised of adding chemotherapy to the HIFU treatment with the aim of destroying residual cells.…”

Section: Introductionmentioning

confidence: 99%

Influence of the docetaxel administration period (neoadjuvant or concomitant) in relation to HIFU treatment on the growth of Dunning tumors: results of a preliminary study

Paparel

Chapelon

Bissery

et al. 2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

The objective of this study was to evaluate mechanisms of the synergy between high intensityfocused ultrasound (HIFU) and docetaxel and to determine the best sequence of chemotherapy administration in relation to HIFU treatment for obtaining optimum control of tumoral growth. A total of 15 days after s.c. implantation of the tumor, 52 Copenhagen rats studied were randomized in 4 groups of 13: controls, docetaxel alone (group 1), HIFU and docetaxel concomitant (group 2) and HIFU and docetaxel administered 24 h before treatment (group 3). The number of HIFU shots was calculated in order to cover 75% of the tumor volume. The effects of docetaxel, HIFU and their interaction on tumor volumes were analyzed using a linear regression. The distributions of the tumor volumes were significantly greater in the control group than in the group 1 (P ¼ 0.002) and than in both groups 2 and 3 (Po0.0001 and P ¼ 0.0001). These volumes were also significantly greater in group 1 than in both groups 2 and 3 and there was no difference between the groups 2 and 3. The tumor doubling times were 7.8 days for the group 1, 43.8 days for the group 2, 16.1 days for the group 3 and 5.9 days for the controls. The mechanism of the synergy between HIFU and docetaxel on the growth of Dunning tumors is apparently multifaceted. The results are encouraging because in the two groups of rats treated with the combination of HIFU and docetaxel, the percentage of complete remission was approximately 30%.

show abstract

High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience

Cited by 316 publications

References 20 publications

Transrectal high‐intensity focused ultrasound for treatment of localized prostate cancer

Transrectal high‐intensity focused ultrasound for treatment of localized prostate cancer

The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population

Influence of the docetaxel administration period (neoadjuvant or concomitant) in relation to HIFU treatment on the growth of Dunning tumors: results of a preliminary study

Contact Info

Product

Resources

About